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Role of microglial amylin receptors in
mediating beta amyloid (Aβ)-induced
inflammation
Wen Fu1, Vlatka Vukojevic1, Aarti Patel1, Rania Soudy1,2, David MacTavish1, David Westaway1,3,4, Kamaljit Kaur5,
Valeri Goncharuk6 and Jack Jhamandas1*

Abstract
Background: Neuroinflammation in the brain consequent to activation of microglia is viewed as an important
component of Alzheimer’s disease (AD) pathology. Amyloid beta (Aβ) protein is known to activate microglia and
unleash an inflammatory cascade that eventually results in neuronal dysfunction and death. In this study, we
sought to identify the presence of amylin receptors on human fetal and murine microglia and determine whether
Aβ activation of the inflammasome complex and subsequent release of cytokines is mediated through these
receptors.
Methods: The presence of dimeric components of the amylin receptor (calcitonin receptor and receptor activity
modifying protein 3) were first immunohistochemically identified on microglia. Purified human fetal microglial
(HFM) cultures were incubated with an in vivo microglial marker, DyLight 594-conjugated tomato lectin, and loaded
with the membrane-permeant green fluorescent dye, Fluo-8L-AM for measurements of intracellular calcium [Ca2+]i.
HFM and BV-2 cells were primed with lipopolysaccharide and then exposed to either human amylin or soluble
oligomeric Aβ1–42 prior to treatment with and without the amylin receptor antagonist, AC253. Changes in the
inflammasome complex, NLRP3 and caspase-1, were examined in treated cell cultures with Western blot and
fluorometric assays. RT-PCR measurements were performed to assess cytokine release. Finally, in vivo studies were
performed in transgenic mouse model of AD (5xFAD) to examine the effects of systemic administration of AC253
on markers of neuroinflammation in the brain.
Results: Acute applications of human amylin or Aβ1–42 resulted in an increase in [Ca2+]i that could be blocked by
the amylin receptor antagonist, AC253. Activation of the NLRP3 and caspase-1 and subsequent release of cytokines,
TNFα and IL-1β, was diminished by AC253 pretreatment of HFMs and BV2 cells. In vivo, intraperitoneal
administration of AC253 resulted in a reduction in microglial markers (Iba-1 and CD68), caspase-1, TNFα, and IL-1β.
These reductions in inflammatory markers were accompanied by reduction in amyloid plaque and size in the brains
of 5xFAD mice compared to controls.
Conclusion: Microglial amylin receptors mediate Aβ-evoked inflammation, and amylin receptor antagonists
therefore offer an attractive therapeutic target for intervention in AD.
Keywords: Microglia, Amylin receptor, β-amyloid, AC253 peptide, Inflammasome, NLRP3, Caspase-1, Cytokines,
Alzheimer’s disease
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Background
Alzheimer’s disease (AD), the most common form of dementia, is characterized by synaptic loss, deposition of
misfolded proteins (amyloid beta protein, Aβ, and hyperphosphorylated tau), and neuroinflammation [1]. Microglia, the main immune cells in the brain, appear central
to the initiation and progression of neuroinflammation
in AD [2–4]. These cells are activated and recruited to
amyloid plaques, phagocytose Aβ, and secrete cytokines
[5]. Initiation of such an inflammatory cascade results
from Aβ recruitment of intracellular cytosolic multiprotein complexes termed “inflammasomes” and the subsequent activation of microglial caspase-1 [6–8]. The
inflammasome NLRP3, a member of the PYHIN family
of proteins, and ASC, an adaptor protein, are deemed to
be important in the context of neurodegenerative processes [9]. Caspase-1 generates inflammatory responses
through cleavage and release of the injurious cytokines,
IL-1β and IL-18, on to adjacent neurons [6, 10]. The release of such inflammatory cytokines also elicits upregulation of Aβ via increased APP processing [11], thus
perpetuating a vicious cycle of Aβ-induced neuronal
damage. Therefore, mechanisms whereby Αβ activates
microglia to initiate this inflammatory cascade are crucial to understanding the interplay between microglia
and neuronal viability in AD. Αβ is postulated to be
endocytosed into murine microglia [7] or alternately
interact with a variety of putative target receptors on the
microglial membrane [12, 13]. In the course of examining the presence of amylin receptors on neurons, we
made the surprising observation that amylin receptors
are also present on microglia [14, 15]. We thus hypothesized that microglial amylin receptors may serve as a
portal of expression of Aβ-induced inflammatory
responses.
Amylin receptors (AMYs) consist of dimerized calcitonin receptor (CTR) with receptor activity-modifying
proteins (RAMPs) and belong to class B GPCR. Amylin,
the endogenous peptide that binds to the amylin receptor, mediates glycemic regulation, control of energy balance, and cognitive processes and modulates innate
immunity through regulatory T cells [16–18]. We have
previously shown that the deleterious effects of Aβ on
cultured human and rat neurons are expressed through
the amylin receptor and that amylin receptor antagonists, such as AC253, are neuroprotective against Aβ
toxicity [14, 19]. Moreover, application of amylin receptor antagonists reverses impairment of Aβ or human
amylin (hAmylin)-induced depression of hippocampal
long-term potentiation, a cellular surrogate of memory
[20]. Herein, we show that amylin receptors are not only
present on human fetal and murine microglia but are
functional in mediating Aβ-induced activation of an
intracellular inflammatory cascade that results in the
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release of cytokines. Chronic systemic administration of
cyclized form of the amylin receptor antagonist, AC253
(cAC253), which is readily brain penetrant, reduced
markers of microglial activation and cytokine release in
a mouse model of AD [15]. We also observed a parallel
decrease in amyloid plaque formation in cAC253-treated
AD mice.

Methods
All experiments were conducted in compliance with the
guidelines set by the Canadian Council for Animal Care
and with the approval of the Human Research Ethics
Board and Animal Care Use Committee (Biomedical
Sciences) at the University of Alberta.
Cell cultures

Two different types of microglial, primary cultures of
human fetal microglia and mouse microglial BV2 cell
line, were used for in vitro testing of amylin receptor
function. This approach provided confirmation of the
presence of microglial amylin receptors across species
and cross-validated our observations on the function of
amylin receptors in both primary cell cultures and a frequently used cell line. Primary mixed glial cultures were
prepared from 12- to 15-gestational-week fetuses as previously reported [21, 22]. Briefly, the meninges and
blood vessels were removed and the brain tissue was
washed in minimum essential medium and mechanically
dissociated by repeated trituration through a 20-gauge
needle. Cells were centrifuged at 1500g for 10 min and
re-suspended in minimum essential medium with 10%
fetal bovine serum. The cultures were grown in a 5%
CO2 humidified incubator at 37 °C. After mixed glial
cultures were completely confluent, human fetal microglia (HFM) were isolated by shaking flasks at 100 rpm
(IKA KS-260, IKA Works, Wilmington, NC) for 1 h at
37 °C. The media was then collected and centrifuged at
2500 RCF for 5 min at 4 °C. Cell pellets were resuspended in microglia plating media (MEM + 10% FBS
+ 1% penicillin/streptomycin). HFM were plated at a
2 × 105 cells per milliliter density, and microglia were
allowed to attach overnight before further use for experiments. BV2 cells (kindly provided by Dr. T. Trang,
University of Calgary) were cultured in DMEM/F12
media with 10% FBS. For all in vitro experiments, primary human fetal microglial cultures and BV2 cell cultures, each experiment was performed on a fresh batch
of cell cultures and repeated a minimum of four times.
Statistical analysis was performed on mean data.
In order to characterize the antagonist activity of
cAC253 at subtypes of amylin receptors, we compared
hAmylin-generated cAMP responses in stably expressed
AMY1, AMY2, and AMY3 and CTR receptors in
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HEK293 cells and wild-type HEK (HEK-WT) cells
(Additional file 1).

Western blot

Frozen brain tissues or cultured cells were homogenized
in cold RIPA buffer with protease inhibitors and proteins
were quantified with BCA assay (BioRad, Mississauga,
ON, Canada). Proteins were loaded at 50 μg per lane on
a 12% polyacrylamide gel. Proteins were transferred to
nitrocellulose membrane and then blocked with LiCor
blocking buffer. Blots were further incubated with primary antibodies overnight at 4 °C on a shaker. Primary
antibody used for Iba1 (1:500, rabbit, Wako), CD68
(1:500, mouse monoclonal, Dako), caspase-1 (1:1000,
rabbit, Abcam), NLRP3 (1:1000, rabbit, Millipore), and
β-actin (1:10,000 mouse, Sigma-Aldrich). IRDye 800CW
goat anti-rabbit and IRDye 680CW goat anti-mouse
(LiCor, 1:10,000) were used as secondary antibodies.
Blots were imaged using LiCor Odyssey image system.

ELISA (enzyme-linked immunosorbent assay)

Mouse brain cytokines, TNFα (Invitrogen), IL-6 (interleukin-6, Abcam), and IL-1β (Thermoscientific) were
quantified using colorimetric ELISA kits following the
protocol provided. In brief, hemi-brains were homogenized on ice for 3 h in RIPA buffer with protease inhibitor. The homogenized brain was centrifuged at 21,000g
for 20 min at 4 °C. The supernatant was collected and
diluted with PBS buffer pH 7.4 (1:100) prior its plate
loading. Standard curves were plotted using the cytokine
standards provided in the ELISA kits. All samples were
analyzed in duplicate. The plate is measured at 450 nm
and data expressed as pg/mg wet tissue.

Cytokines PCR assay

The PCR array for TNFα, IL1β, and IL23 gene expression used the RT2 Profiler PCR Array system (96-well
assay plate, SABiosciences) following product instruction. Briefly, HFM were plated in a six-well plate for
24 h, pre-treated with/without AC253 10 μM for 24 h,
and then exposed to either hAmylin (1 μM) or Aβ1–42
(1 μM) for 6 h. RNA was isolated with Rneasy Mini kit
(Qiagen) as per the product instructions. For each PCR
Array, 4 μg of total RNA were used to prepare cDNA
with the appropriate first strand kit from SABiosciences.
The cDNA was characterized on the iCycler® iQ RealTime PCR System (Bio-Rad Laboratories) using the RT2
Profiler PCR Arrays. The resulting raw data were then
analyzed using the PCR Array Data Analysis Template
and expressed as gene expression fold-change after treatment compared to the control untreated HFM cultures.
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Immunofluorescent-histological staining

For cultured cell immunofluorescent staining, cells were
plated on Lab-TEK chamber slide (ThermoFisher) and
fixed with 4% paraformaldehyde (PAF) in PBS, then
permeabilized with 0.3% Triton X-100 in PBS and
blocked with 2% BSA + 10% goat serum for 1 h. Primary
antibodies used Iba-1 (1:100, Dako), CTR (1:50, ThermoFisher, Catalog # PA1-84457, Lot # QJ2098825 and
RI2275863), RAMP3 (1:100, Abcam), Aβ (6E10, 1:300,
Covance), and NLRP3 (1:300, Millipore) followed fluorescent secondary antibody (goat anti-mouse Alexa
Fluor-546 and goat anti-rabbit Alexa Fluor-488) and
were nuclear-stained with DAPI (0.1 μg/ml, ThermoFisher). Fluorescent dyes, DyLight-594 Lectin (Vector),
HiLyte 555-labled Aβ1–42 (AnaSpec), and caspase-1
(FAM-FLICA caspase 1 kit, ImmunoChemistry Technologies) were used following product instruction. Fluorescent microscopy images were acquired with an
Axioplan-2 fluorescence microscope with AxioVision
software (Carl Zeiss Ltd., Toronto, ON, Canada).
For human brain immunohistochemical staining, 20μm-thick brain sections were cut from 1-cm-thick coronal block of the human inferior temporal gyrus (IFG)
of an AD brain (Braak Stage 6) obtained from the
Netherlands Brain Bank. Prior to immunohistochemistry, the sections were pretreated with absolute methanol
and 3% hydrogen peroxide for 10 min to avoid visualizing endogeneous peroxidase activity, followed by three
10 min (3 × 10 min) washes in TBS (Tris-buffered saline). Then, they were incubated overnight at 4 °C with
the rabbit polyclonal anti-CTR antibody (ThermoFisher
Scientific) at a working dilution 1:20 in Supermix (TBS
containing 0.3% Triton X-100 and 2.5 mg/ml gelatin).
The next day, the sections were washed in TBS (3 × 10
min) and then incubated in biotinylated goat anti-rabbit
IgG, diluted 1:400 in Supermix for 2 h at room
temperature. Following incubation, the sections were
washed in TBS (3 × 10 min) and processed by the
avidin-biotin complex (ABC) (Vector Laboratories, Burlingame, CA) for 2 h at room temperature. After washing in TBS (3 × 10 min), reaction products of dark blue
color were visualized with 3,3′-diaminobenzidine-4HCl
(20 mg/100 ml, Sigma) in TBS containing 0.2% ammonium nickel sulphate and 3% H2O2. Several sections
were immunostained for CTR as mentioned above and
after final washing in TBS were incubated overnight at
4 °C with either Iba-1 antibody (1:100, Dako) or RAMP3
rabbit polyclonal antibody (Abcam, Catalog # ab78017,
Lot # 816327; Catalog # ab197372, Lot # GR2042843) at
working dilution of 1:500 in Supermix. The next day, the
sections were washed in TBS (3 × 10 min) and then incubated in biotinylated goat anti-rabbit IgG diluted
1:400 in Supermix for 2 h at room temperature. Further,
the sections were washed 3 × 10 min in TBS and
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processed with ABC for 2 h at room temperature. After
washing 3 × 10 min in TBS, the sections were treated
with 3,3′-diaminobenzidine-4HCl (20 mg/100 ml,
Sigma) in TBS containing 3% H2O2, resulting in the reaction product of yellow color. Thus, after CTR + Iba-1
dual immunostaining of the IFG sections, the neuronal
final reaction product of dark blue color was associated
with the presence of the CTR whereas deposit of yellow
color was coupled with Iba-1 or RAMP3. Brightfield images were acquired on Axioplan 2 microscope (Zeiss)
with AxioVision software (ver 4.8.2, Zeiss). The ability of
the CTR and RAMP3 antibodies to detect these proteins
was verified using AMY3-HEK293 transfected cells and
wild-type HEK293 cells (Additional file 1 and Additional file 2: Figure S1A). We also performed siRNA
RAMP3 transfections of BV2 microglial cells and compared detection of the RAMP3 protein in these cells
compared to non-transfected cells (Additional file 1 and
Additional file 2: Figure S1B).
For in-cell Western blot cyclic adenosine monophosphate (cAMP) quantification, mouse monoclonal anticAMP (R&D Systems) was used as a primary antibody
and IRDye 700 goat anti mouse antibody (LI-COR) was
used as a secondary antibody. Plates were imaged using
an Odyssey Infrared Imaging System (LI-COR), and the
integrated intensity was normalized to the total cell
number on the same well as previously described [23].
Ca2+ imaging

Ca2+ concentration were monitored with confocal microscopy as described previously [23, 24]. Briefly, HFMs
were plated on glass coverslips pre-coated with poly-Lornithine and incubated at 37 °C for 12–36 h. Then, incubated with 5 μM of membrane-permeant fluorescent
Ca2+-sensitive dye Fluo-8L-AM (AAT Bioquest, Inc.,
Sunnyvale, CA) for 40 min at room temperature (20–
23 °C) within < 2 h before imaging. For Ca2+ imaging,
the superfusate of ion content similar to extracellular
brain fluid thus contain the following: 130 mM NaCl,
4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES,
and 10 mM glucose (pH 7.35) was applied at a rate of
3 ml/min using a roller pump (Watson-Marlow Alitea,
Sin-Can, Calgary, AB, Canada). Aβ1–42 and hAmylin
were dissolved in sterile bidistilled water at 1 mM stock
solution and incubated at room temperature for 10 min
before dilution with superfusate for the final used concentrations. Fluorescence intensity was monitored with a
FV-300 laser-scanning confocal microscope (Olympus
FV300, Markham, Ontario, Canada) equipped with an
argon laser (488 nm) and excitation/emission filters
(FF02-520/28-25; Semrock, Inc.) for an emission wavelength at 514 nm, measured with a numerical aperture
of 0.95 20× XLUMPlanF1 objective (Olympus). Images
were acquired at scan rates of 1.25–1.43 per second
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using a 2–3× digital zoom at full-frame (512 × 512 pixel)
resolution. Regions of interest were drawn around distinct cell bodies, and analysis of time courses of change
in fluorescence intensity were generated with FluoView
software (version 4.3; Olympus).
Peptides and reagents

AC253 peptide was cyclized to improve its stability and
brain penetration when administered systemically [15].
To cyclize the AC253 peptide (cAC253) via the flanking
D-cysteines, the crude peptide (61.2 mg) was dissolved in
0.1 mM Tris buffer pH 8.3 having 20% of DMSO to accelerate disulfide bond formation, and the mixture was
stirred at room temperature in an open flask for 48 h
and further purified on RP-HPLC (reversed phase highperformance liquid chromatography).
Soluble oligomeric Aβ1–42 or the inverse sequence
peptide Aβ42–1, hAmylin, and AC253 were prepared according to published protocols [14, 25]. Human amylin
and AC253 were purchased from American Peptide
(Sunnyvale, CA) and Aβ peptides from rPeptide (Bogart,
GA). The human amylin was prepared in 1 mM stock
solution in water and further diluted to the final application concentration with cell culture media as previously
described [14].
In vivo experiments and mouse brain tissue processing

For in vivo experiments, intraperitoneal injection (ip)
administration of cAC253 was carried out in transgenic
5XFAD mice [15], and wild-type littermate control mice
(both male and female) were obtained from Dr. David
Westaway (University of Alberta). These mice were
equally and randomly distributed into four groups, TgNS (n = 10), Tg-cAC253 (n = 10), Wt-NS (n = 10), and
Wt-cAC253 (n = 10). Mice received ip either normal saline (NS) or cAC253 (200 μg/kg) three times a week
starting at 6.5 months of age for 5 weeks. Mice were
housed under standard laboratory conditions (12/12-h
light/dark cycle, lights on at 0600 h) with a room
temperature of 21 °C. Water and food were available ad
libitum. After completion of treatments, all mice were
sacrificed with an overdose of isoflourane anesthetic and
perfused transcardially with saline, and the brains were
harvested. The right hemisphere was frozen for biochemical analysis (Western blot, ELISA), and the left
hemisphere was fixed with PAF for 4 h at 4 °C. These
brain tissues were further processed with modified
CLARITY protocol (http://www.chunglabresources.com/
cl1#cl-protocol). Briefly, the fixed brain tissue was transferred to hydrogel monomer solution (4% acrylamide,
4% PFA, and 1xPBS (phosphate-buffered saline)) at 4 °C
for 24 h and, subsequently, to a 24-well plate, merged in
fresh hydrogel solution, and the tissue was brought to
37 °C till formation of the gel. Thick sagittal slices
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(400 μm) were cut on an HR2 Slicer (Sigman Electronic,
Germany). The thicker brain sections were cleared with
8% SDS in PBS for 24 h, followed by 0.3% Triton X-100
in PBS for 24 h, blocking the section in 2%BSA-10% goat
serum for 4 h. A modified thioflavin S staining was used
for detecting Aβ plaques. Briefly, the brain sections were
rinsed with distilled water, dropped with thioflavin S
(0.0125% in 50% ethanol) for 5 min, further washing
with 50% ethanol and water. Then, these sections were
incubated with CD68 antibody (1:50, DAKO) at 4 °C for
overnight. After washing with PBS, these sections were
incubated with goat-anti mouse Alexa-fluor546 (1:200,
Invitrogen) at RT for 4 h. Sections were cleared with 8%
SDS for 24 h followed by a 24-h wash with PBS-TritonX100 solution. Images were visualized using fluorescence microscopy (Axioplan-2, Carl Zeiss Ltd). Amyloid
plaque size and area were analyzed with Image J
software.
Statistical analysis

The statistical data are presented as mean ± SEM unless
otherwise specified. Significance was determined by oneway analysis of variance (ANOVA), followed by Tukey’s
post hoc test with Prism software (GraphPad Prism 5,
GraphPad Software, San Diego, CA). Differences
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between groups were considered to be significant at
p < 0.05.

Results
Microglial cells expressed functional AMY receptors

In primary HFM cultures, the microglia population comprises more than 90% of cells as judged by staining with
microglial markers, Iba-1, and DyLight 594 lectin
(Fig. 1a). To establish AMY expression in these microglial cells, we first immunohistochemically identified the
presence of CTR and RAMP3 (Fig. 1b). We next
assessed functionality of AMYs using live-cell calcium
imaging (with Fluo-8) and confocal microscopy of identified microglia (Fig. 1c). Bath applications of either
monomeric human amylin (hAmylin) or soluble oligomeric Aβ1–42 (1 μM) to HFM for 30 s produced a robust
Ca2+ increase within 1 min after entry of the peptide
within the imaging chamber. These Ca2+ increases displayed a sharp peak and returned to base line within
2 min (Fig. 1e, f ), and they are similar to responses
evoked by these peptides in HEK293 cells expressing the
AMY3 receptor subtype [23]. The transient elevations in
Ca2+ due to hAmylin or Aβ1–42 applications were abolished by prior application of the amylin receptor antagonist, AC253 (Fig. 1h, i), suggesting that these responses

Fig. 1 Microglial cells express functional amylin receptors. a Primary cultures of human fetal microglia (HFMs) that are stained with microglial
antibody, Iba-1 (green), and DyLight-594-labeled lectin (red). b These primary cultured HFMs were also stained for the two dimeric proteins that
are components of the amylin receptor 3 (AMY3) subtype, the calcitonin receptor (CTR), and the receptor-associated membrane protein 3 (RAMP3). c
Cultured HFMs were loaded with the fluorescent intracellular calcium dye, Fluo-8L-AM (green), and with lectin (red), an in vivo microglial
marker. Arrowheads indicate cells from which Ca2+ signals were recorded. The same cell culture is also stained with lectin (red). The field
in c shows that a majority of cells are microglia. d Summary of data on intracellular calcium changes after human amylin (hAmylin) and
Aβ1–42 without and with application of the amylin receptor antagonist, AC253 in HFM (*p < 0.05, n = 123 cells in 12 culture wells from
four different batch of the culture cells). The candidate traces for intracellular calcium changes are illustrated in e–i. Elevations of Ca2+induced by
acute (30 s) application of either hAmylin (1 μM, e) or Aβ1–42 (1 μM, f). The changes in Ca2+ were blocked by AC253 (10 μM, g–i). Traces correspond to
cells identified in c with arrowheads. Scale bar = 20 μm
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are AMY receptor-mediated. AC253 applied alone did
not evoke any alterations in intracellular Ca2+ levels
(Fig. 1g). Pooled data shown in Fig. 1d are from 123
HFM in 12 culture wells from four different batches of
HFM cultures. Finally, we also confirmed, using inferior
temporal gyrus sections from autopsied AD patient
brain, that adult human microglia were immunopositive
for CTR and RAMP3 (Fig. 2a–e). In addition, BV2 cells,
a mouse microglia cell line, also expressed amylin receptors (Fig. 2f, g). In these cells, exposure to Aβ1–42,
(1 μM) resulted in an uptake of the peptide into the
microglia and formation of plaque-like structures on the
cell surface as determined by thioflavin S staining
(Fig. 2g).
Aβ induces AMY receptor-mediated microglial immune
responses

We next sought to examine the potential role of microglial AMY receptors in Aβ-induced activation of the
intracellular inflammasome cascade. We observed levels
of NLRP3, the best studied of inflammasomes in the
context of AD, to be low under basal conditions but increased significantly after hAmylin or Aβ stimulation
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(Fig. 3a). This stimulated increase in the NLRP3 expression was attenuated in the presence of the AMY antagonist, AC253, thus identifying a role for AMY receptors
in activation of the inflammasome cascade (Fig. 3b).
Western blot analysis further confirmed AMY receptormediated changes in NLRP3 expression (Fig. 3c, d).
Since inflammasomes function as intracellular sensors
for danger signals and in response trigger activation of
caspase-1 and subsequent cleavage and release of cytokines, we also examined the role of AMY receptors in
these downstream events. Both Aβ and hAmylin increased caspase-1 expression in HFM and BV2 cell cultures, a response that was blunted by AC253 (Fig. 4a, b).
Additionally, using RT-PCR assay, we also identified Aβ
and hAmylin-mediated increases in IL1β, and TNFα, but
not IL23, that were significantly attenuated by AC253
(Fig. 4c).
In vivo therapeutic targeting to block AMYs reduces brain
inflammation and amyloid plaque formation in transgenic
animal model of AD

We have recently synthesized a cyclized form of AC253
(cAC253), which retains the neuroprotective properties

Fig. 2 Amylin receptors on microglia in human Alzheimer’s disease brain and BV2 microglial cells. a, b Section from the inferior frontal gyrus of
the AD patient (Braak Stage 6) after dual immunostaining both with the antibody to microglial marker Iba-1 (yellow) and calcitonin receptor (CTR)
(dark blue). Arrows show microglial cells expressing both Iba-1 and CTR; thin arrows point to microglial cells expressing only Iba-1. c, d Single
microglial cells are presented at a higher magnification, with thin arrows pointing to Iba-1 location (yellow) and arrows pointing to the CTR
location (dark blue). e Coronal section from the inferior frontal gyrus of the AD patient after double immunohistochemical staining with
antibody against CTR and receptor activity modifying protein 3 (RAMP3). Notice the microglia-like profile (mgl) expressing both CTR (blue)
and RAMP3 (yellow). f BV2 microglial cells expressed CTR (red). g These BV2 cells were cultured in the presence of Aβ1–42 1 μM for 24 h.
The Aβ was taken up into the cells and formed plaque-like structures stained with thioflavin S (green). Scale bars = 10 μm
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Fig. 3 Amylin receptor mediates activation of inflammasomes in microglia. a Increased activation of the inflammasome, NLRP3 (green), following
application of either Aβ1–42 or hAmylin human fetal microglial (HFMs) cultures. Aβ is identified with immunostaining with 6E10 antibody and shows as
yellow on account of its co-localization with NLRP3. b BV2 cells (murine microglial cell line) treated either Aβ1–42 or hAmylin (2 μM) for 24 h show a
similar increase in NLRP3 staining as in HFMs that is attenuated by 16 h pre-treatment with AC253 (10 μM). c Summary of amylin receptor mediated
changes in NLRP3 observed and quantitated from Western blots, an example of which is shown in d. **p < 0.01. Scale bar = 20 μm

Fig. 4 Aβ induces upregulation of caspase-1 and pro-inflammatory cytokines in human fetal microglia (HFMs) via amylin receptor. a, b Aβ1–42 or
hAmylin increase caspase-1 expression that is detected by a fluorometric assay (green). Pre-treatment of HFMs with amylin receptor antagonist,
AC253 blocks caspase-1 expression. c RT-PCR detection of cytokines (TNFα, IL-10, IL-1β, and IL-23) in HFMs treated with either hAmylin, Aβ1–42, or
AC253. Pre-treatment of HFMs with AC253 markedly attenuates upregulation of TNFα, IL-10, and IL-1β, but not IL-23. *p < 0.01. Scale bar = 20 μm
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of the linear form of the peptide but is proteolytically
stable and highly brain-penetrant when administered intraperitoneally [15]. The pKa = 6.942 for the cAC253
peptide was calculated from Molecular Operating Environment (MOE) from Chemical Computing Group
(Montreal, QC, Canada). The cAC253 also demonstrated
a higher level of antagonist activity at AMY receptors
with IC50, 0.3 μM, versus AC253, 0.85 μM, using in-cell
western blot detection [15]. In HEK293 transfected cells,
cAC253 demonstrated similar activity as AC253 and
blocked hAmylin activation of AMY3 and AMY1 receptors (Additional file 3: Figure S2). We also tested the
ability of cAC253 (at different concentrations) to competitively antagonize human amylin-generated cAMP responses across full range of concentrations. We
examined the effects of chronic systemic administration
of cAC253 on changes in amyloid pathology and inflammatory markers in a transgenic mouse model of AD,
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5xFAD. Six and a half-month-old 5xFAD mice that received 5 weeks of cAC253 treatment (ip, three times a
week) demonstrated significant reduced amyloid plaque
formation, and we observed less number of activated
microglial cells compared to 5xFAD mice treated with
normal saline (NS) injections (Fig. 5a, b). Aβ deposition
was significantly reduced as measured by either the
number of Aβ plaques, or total area of Aβ-positive profiles in the cAC253-treated 5xFAD animals compared to
those receiving NS (Fig. 5b). Wt mice showed no Aβ
deposits. Protein expression levels of microglial
markers Iba-1 and CD68 (activated microglia), inflammasome NLRP3, and caspase-1 were significantly reduced (approximately 30%) in cAC253-treated 5xFAD
group compared to NS treatment (Fig. 5c, d). Additionally, levels of cytokines IL-1β and TNFα measured by ELISA were also significantly reduced after
ip cAC253 treatment (Fig. 5e).

Fig. 5 Blocking the amylin receptor reduces amyloid plaque formation and inflammatory markers in transgenic AD mice. a Transgenic AD mice
(5xFAD), amyloid plaques in brains of treated with cyclized AC253 (cAC) or normal saline (NS) mice reveals significant reduction of the amyloid
plaque (green, stained with thioflavine S). The activated microglia (red, stained with CD68 antibody) are also reduced. The total amyloid plaque
number and plaque size are significantly reduced (b). c Markers of brain microglial activation (Iba-1, CD68) and inflammation (caspase-1 and
TNFα) in the two groups of 5xFAD mice (NS, cAC253) were detected by Western blot and quantified (d). e ELISA analysis of brains from the same
animals shows that IL-1β and TNFα are significantly reduced with cAC253 treatment. *p < 0.05. Scale bar in a = 200 μm
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Discussion
Although recent studies indicate that amylin and amylin
receptor are involved in microglia-mediated neuroinflammation in AD mice [26, 27], this study shows for
the first time immunohistochemical presence of amylin
receptors on human and murine microglia, which serve
as a portal for the expression of the inflammatory effects
of Aβ in the brain. Specifically, amylin receptors present
on human microglia are functional in that applications
of either monomeric hAmylin or soluble oligomeric
Aβ1–42 results in an increase in cytosolic Ca2+, a response that is accompanied by activation of the inflammasome, NLRP3, and caspase-1 with the subsequent
release of pro-inflammatory cytokines, IL-1β and TNFα.
Blockade of the amylin receptors with an amylin receptor antagonist, AC253, results in an attenuation of these
inflammatory mediators. In a transgenic mouse model of
AD, systemic administration of cAC253 leads to an improvement in spatial memory and learning [15], that is,
accompanied by diminution of the amyloid burden,
and an attenuation of microglial markers within the
brain. Collectively, these observations suggest a possible role for the amylin receptor as a target in the
therapeutics of AD.
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Increasing evidence suggests that AD pathogenesis involves multiple interacting compartments that include
neuronal and synaptic disruption, vascular pathology,
and neuroinflammation [1, 28]. Of these, neuroinflammation mediated primarily by microglia, which are critical regulators of immune responses, is a key feature of
early AD. Microglia are implicated in clearance of Aβ either by phagocytosis or binding to receptors on microglial plasma membrane [28–33]. In vitro and in vivo
studies have shown that consequences of Aβ interactions
with microglia include lysosomal damage, activation of
the NLRP3 inflammasome complex, and the release of
cytokine IL-1β in a caspase-1-dependent manner [9].
The uncontrolled release of inflammatory cytokines also
elicits upregulation of Aβ via increased APP processing
[11], thus perpetuating a vicious cycle of Aβ-induced
neuronal damage that is a feature of late AD [28].
Microglial receptors therefore present an attractive target to mitigate both neuroinflammation and neuronal
toxicity induced by amyloid as depicted in our working
model (Fig. 6). We have previously shown that a
pharmacological blockade or genetic depletion of the
amylin receptor in the human neuronal cell culture
model protects against the Aβ-induced toxicity [14, 34].

Fig. 6 Proposed model for the role of microglial and neuronal amylin receptors in mediating the amyloid beta (Aβ)-induced neurodegeneration.
Amylin receptors, comprised of calcitonin receptor (CTR) and receptor activity modifying protein 3 (RAMP3), are expressed on both neurons and
the microglia. The expression of amylin receptors on microglial cells is increased in response to inflammatory triggers, such as lipopolysaccharide
(LPS), resulting in activation of these cells. Interaction of Aβ with amylin receptors on the activated microglia leads to increased production and
release of cytokines, which act directly on neurons to produce cell death and additionally augment the production of Aβ via processing of the
amyloid precursor protein (APP). This Aβ, in turn, interacts with neuronal and microglial amylin receptors to produce cell death. The amylin
receptor antagonist AC253 acts on both the neuronal and microglial receptors to block the detrimental effects of Aβ and affords protection
against the neuronal degeneration
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Here, we show that blockade of microglial amylin receptors with an amylin receptor antagonist, AC253 in vitro,
results in attenuation of NLRP3-mediated inflammatory
cascade and diminished cytokine release. Furthermore,
in a mouse AD model with systemic administration of
cAC253 results in attenuation of key indices of brain
inflammation-activated and reactive microglia (Iba-1,
CD68), the inflammasome NLRP3, caspase-1, and proinflammatory cytokines, IL-1β and TNFα.
In transgenic mouse models of AD, microglial activation
is observed to parallel accumulation of amyloid [35, 36]
and a similar relationship has also been reported for the
human AD using PET ligands [36, 37]. In our study, we
administered the amylin receptor antagonist cAC253 intraperitoneally to 5xFAD mice at six and a half months of
age, a time point corresponding to the presence of pathological features such as the amyloid accumulation and
neuroinflammatory changes [15]. In these in vivo experiments, we chose to use cAC253 on account of its superior
stability, pharmacokinetic profile, and brain penetrability
when administered systemically compared with linear
form of the peptide AC253 [15]. Five weeks posttreatment with cAC253, we observed a significant reduction in both the amyloid burden and indices of neuroinflammation in a manner similar to that observed in vitro.
Based on these findings, we conclude that the amylin receptor blockade has the potential to mitigate Aβ-induced
microglial activation, a key event in AD pathogenesis, and
subsequent cytokine-induced neuronal death.
As a neuroendocrine hormone, amylin mediates glycemic regulation, energy balance control, and cognitive/
motivational processes [18]. Human amylin also modulates autoimmunity and innate inflammation through
regulatory T cells [16, 17]. Amyloid precursor protein
(APP) and Aβ interact with variety of G-protein-coupled
receptors (GPCRs) including amylin receptors [38].
Amylin receptors (AMYs) are a dimerized calcitonin receptor (CTR) with receptor activity-modifying proteins
(RAMPs) and belong to class B GPCRs. We have previously shown that hAmylin and Aβ preferentially activate
AMY3 receptor subtype resulting in downstream activation of MAPK and Akt signaling pathways that could be
blocked with amylin receptor antagonist, AC253 [23]. At
a functional level, application of either AC253 or pramlintide (marketed as a synthetic analog of amylin) attenuate hAmylin- and Aβ-induced depression of
hippocampal long-term potentiation, a cellular surrogate
of memory [20, 39]. Pramlintide when administered systemically to transgenic AD mice has been shown to reduce amyloid burden in the brain through promoting an
efflux of Aβ across the blood brain barrier [40, 41].
Cyclized AC253 may reduce brain amyloid through a
similar mechanism. Additionally, we suggest that
cAC253, which readily crosses the blood brain barrier,
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could block both the neuronal and microglial amylin receptors, thereby diminishing the deleterious effects of elevated levels of Aβ in transgenic AD mice. As a
consequence, cAC253-treated AD mice demonstrate not
only improved spatial memory as we have reported [24],
but also an attenuation of neuroinflammation.

Conclusions
In this study, we provide evidence that functional amylin
receptors are expressed on both human and murine
microglia and mediate Aβ-induced activation of the inflammatory cascade of NLRP3 and caspase-1 with subsequent release of cytokines. Amylin receptor antagonism
can attenuate these pro-inflammatory events in vitro.
Chronic administration of such an antagonist results in
improvement in amyloid burden and inflammatory
markers in an AD mouse model. This supports the idea
inflammatory changes in the brain that contribute to
cognitive dysfunction in AD may, in part, be mediated
via the amylin receptor. Furthermore, amylin receptor
antagonists are capable of attenuating Aβ-evoked inflammation. Thus, amylin microglial receptors could
provide novel treatment for AD specifically by targeting
neuroinflammation, an early event in this disease.
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cells. B, in BV2 cells, RAMP3 protein expression shows a marked decreased
after RAMP3 siRNA transfection compared to the control non-transfected
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